Lexaria Bioscience Corp. 8-K Summary
Business Context and Reporting Period
This Form 8-K Current Report, dated August 31, 2016 (signed September 2, 2016), details the closing of the final tranche of a private placement equity financing by Lexaria Bioscience Corp. The company is incorporated in Nevada with principal executive offices in Vancouver, BC, Canada.
Key Financial Metrics and Transaction Details
- Gross Proceeds: US$196,000 raised from the final tranche.
- Securities Issued: 3,266,666 equity units at US$0.06 per unit.
- Unit Composition: One common share and one non-transferable warrant per unit.
- Warrant Terms: Exercise price of US$0.14; exercisable for two years from issuance.
- Post-Issuance Share Count: 51,288,477 shares issued and outstanding.
- Placement Fees: Corrected to US$3,000 (originally reported as US$6,000).
- Broker Warrants: Corrected to 50,000 (originally reported as 100,000).
Material Changes and Corrections
The filing reports a material correction regarding the transaction costs. On September 2, 2016, Lexaria issued a news release rectifying a clerical error in the August 31 announcement. The placement fees were adjusted downward from US$6,000 to US$3,000, and the number of broker warrants issued was adjusted from 100,000 to 50,000. All other transaction details remain unchanged.
Use of Proceeds and Outlook
All funds raised (US$196,000) are designated for the deployment and marketing of hemp-based food products, investor relations, general and administrative (G&A) expenses, and general working capital. The securities are subject to a hold period of four months and one day in Canada, or six months and one day for resales into the USA under Rule 144.
Investor Verification Checklist
- Verify the corrected placement fee amount of US$3,000 and broker warrant count of 50,000 as per the September 2, 2016 amendment.
- Confirm the total outstanding share count of 51,288,477 following the issuance.
- Review the specific terms of the warrants (US$0.14 strike price, 2-year term) for valuation impact.
- Monitor the deployment of funds toward hemp-based food product marketing as stated in the use of proceeds.